PAVmed Inc. (PAVM)
| Market Cap | 7.94M -31.0% |
| Revenue (ttm) | 148,000 +410.3% |
| Net Income | -16.66M |
| EPS | -7.76 |
| Shares Out | 6.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,098 |
| Open | 1.220 |
| Previous Close | 1.200 |
| Day's Range | 1.100 - 1.290 |
| 52-Week Range | 1.100 - 28.440 |
| Beta | 0.89 |
| Analysts | Buy |
| Price Target | 31.50 (+2,675.33%) |
| Earnings Date | Nov 13, 2026 |
About PAVM
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The companyās lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, incl... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for PAVM stock is "Buy." The 12-month stock price target is $31.5, which is an increase of 2,675.33% from the latest price.
News
PAVmed Earnings Call Transcript: Q3 2026
Medicare payments for EsoGuard and record October test volume mark a key commercial inflection. Veris enrollment accelerated, while Q3 GAAP results included large non-cash fair-value charges and the senior noteās collateral covenant was waived through the SEC filing date.
PAVmed Earnings release: Q3 2026
PAVmed released its Q3 2026 earnings on November 13, 2026, summarizing the period's financial results.
PAVmed Slides: Q3 2026
PAVmed has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 13, 2026.
PAVmed Quarterly report: Q3 2026
PAVmed has published its Q3 2026 quarterly earnings report on November 13, 2026.
PAVmed reports preliminary Q3 adjusted EPS (19c) vs. (62c) last year
Reports preliminary Q3 revenue $41,000 vs. $5,000 last year. PAVmed (PAVM) had cash and cash equivalents of $8.9M, including restricted cash of $5.3M, as of September 30, compared to cashā¦
PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
Lucid Diagnostics' EsoGuard Ā® now fully reimbursed by Medicare nationwide Veris Health achieved implantable physiological monitor design freeze and initiated 90-day GLP animal study ahead of early 202...
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
EsoGuard Ā® now fully reimbursed by Medicare nationwide, launching a new phase of accelerating commercialization with record monthly test volume to start the fourth quarter Conference call and webcast ...
Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc...
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc...
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuardĀ® Study
Largest peer-reviewed study of nonendoscopic esophageal precancer testing to date demonstrates the efficiency and scalability of EsoCheck Ā® cell collection in under two minutes NEW YORK, Nov. 3, 2026 ...
PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, Oct. 30, 2026 /PRNewswire/ -- PAVmed Inc. Ā (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, op...
Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
Conference Call and Webcast at 8:30 AM ET NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagn...
Lucid Diagnostics begins receiving Medicare reimbursement for EsoGuard
Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that it has begun receiving payments from Medicare for its EsoGuard Esophageal DNA Test. The company also closed a $15M privateā¦
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuardĀ® and Closes $15 Million Financing
Lucid is now submitting Medicare claims and receiving payments at EsoGuard's established Clinical Laboratory Fee Schedule rate Series C Preferred Stock private placement with existing long-term shareh...
Lucid Diagnostics Advances Multiple EsoGuardĀ® and EsoCheckĀ® Payment, Billing and Coding Pathways
Medicare Advisory Panel recommends maintaining EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule AMA CPT Editorial Panel approves a new Category III CPT code for non...
PAVmed price target raised to $57 from $56 at Ascendiant
Ascendiant analyst Edward Woo raised the firmās price target on PAVmed (PAVM) to $57 from $56 and keeps a Buy rating on the shares. The firm views the companyās Q2ā¦
PAVmed reports Q2 adjusted EPS (27c) vs. ($1.40) last year
Reports Q2 revenue $33,000 vs. $6,000 last year. āPAVmed (PAVM) saw tangible progress across its core businesses during this past quarter and recent weeks,ā said Lishan Aklog, M.D., PAVmedās Chairmanā¦
PAVmed Earnings Call Transcript: Q2 2026
Progress across all business segments, with Lucid advancing reimbursement, Veris accelerating commercial rollout at OSU, and PortIO achieving positive clinical results. Q2 GAAP net loss was $5.5M, with cash at $3.8M and significant financing activities completed.
PAVmed Quarterly report: Q2 2026
PAVmed has published its Q2 2026 quarterly earnings report on August 14, 2026.
PAVmed Slides: Q2 2026
PAVmed has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 14, 2026.
PAVmed Earnings release: Q2 2026
PAVmed released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physiological monitor achieved development milestones towards upcoming FDA submission Lucid Diagnostics s...
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard Ā® tests Secured first laboratory benefit manager (LBM) EsoGuard coverage policy Conference call and webcast to be held today, August 13...
Lucid announces Concert issued positive coverage policy for EsoGuard test
Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive coverage policy effective July 2026 for n...
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuardĀ® Esophageal DNA Test
Concert's policy recognizes EsoGuard Ā® as the only esophageal precancer test meeting its coverage criteria NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. Ā (Nasdaq: LUCD)Ā ("Lucid" or the...